Pfizer (NYSE:PFE) has been dismissed as a defendant in a major federal lawsuit alleging generic drug price fixing. The court ...

The National Healthcare Security Administration said on Monday that 557 drugs have passed the preliminary review for ...

Indian companies filed 184 Type II DMFs with the US FDA in Q1 2026 against China's 149, reinforcing the country's leadership ...

When life sciences startups think about patent strategy, the natural instinct is to focus on the core science — the novel compound, the ...

On June 16, 2025, the Centers for Medicare & Medicaid Services (CMS) issued a proposed rule, “Medicare Drug Price Negotiation Program and ...

Health advocacy groups have urged the government to reject TRIPS-plus provisions in Thailand's free trade negotiations with the European Union (EU), warning they could delay access to generic ...

In corporate management, nothing is more daunting than uncertainty, not even loss itself. If the scale of a loss can be predicted, countermeasures can ...

While multinational pharmaceutical companies use India to test out their new medicines, India’s researchers rarely lead the ...

Demand for GLP-1 drugs such as semaglutide is exposing capacity gaps across peptide APIs, sterile fill-finish facilities, ...

FDA takes an industry-friendly approach; Trump aide in consideration to lead FDA; Biotech CEOs are suddenly bullish.

Divis Laboratories benefits from strong CDMO demand but faces high valuations, prompting a hold recommendation for investors.

Dr Reddy's whitepaper says weak translational research ecosystem is slowing the journey from laboratory breakthroughs to ...